sar439459
mAbexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 9, 2017 (NCT03192345)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Transforming growth factor beta-1INHIBITOR
TGFB1 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05231668 | Phase 1 | Aug 25, 2022 | Sanofi |
| NCT04729725 | Phase 1 | Feb 9, 2021 | University of Texas at Houston |
| NCT04643002 | Phase 1/Phase 2 (Phase 2) | Dec 28, 2020 | Sanofi |
| NCT03192345 | Phase 1 | Jun 9, 2017 | Sanofi |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sanofi | For profit | 3 | 3 | 2 | 2017 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2021 |
2 organizations
Page 1 / 1